Literature DB >> 30317553

Two- and three-dimensional ultrasonographic features related to histopathology of the uterine endometrial-myometrial junctional zone.

Christina Kjaergaard Rasmussen1, Estrid Staehr Hansen2, Margit Dueholm1.   

Abstract

INTRODUCTION: Our aim was to correlate junctional zone thickening and irregularity (junctional zone disease) and other ultrasonographic features of adenomyosis with the histopathology of the endometrial-myometrial junctional zone.
MATERIAL AND METHODS: Consecutively enrolled premenopausal women (n = 110) scheduled for hysterectomy or transcervical endometrial resection due to abnormal uterine bleeding and/or menstrual pain, underwent two- and three-dimensional transvaginal ultrasonography on the day of surgery with the observer blinded to previous diagnosis. Junctional zone maximum thickness (JZmax ), junctional zone maximum irregularity (JZdif ) and ultrasonographic characteristics of adenomyosis were compared with histopathology of the junctional zone defined as (1) adenomyosis of the inner myometrium, ≥2 mm myometrial invasion without contact to the basal endometrium, (2) serrated junctional zone, >3 mm myometrial invasion with contact to the basal endometrium or (3) linear junctional zone, no or marginal myometrial invasion ≤3 mm with contact to the basal endometrium.
RESULTS: Adenomyosis of the inner myometrium, serrated junctional zone and linear junctional zone was present in 29%, 35% and 35% of the women, respectively. Median JZmax and median JZdif expanded from linear junctional zone (8.5 and 3.3 mm) to serrated junctional zone (10.1 and 4.1 mm) to adenomyosis of the inner myometrium (14.6 and 9.2 mm) (P < 0.05). In addition, the median number of characteristic adenomyosis-like ultrasonographic features increased from the linear junctional zone to the serrated junctional zone to adenomyosis of the inner myometrium (P < 0.05).
CONCLUSIONS: A slightly thickened and/or irregular junctional zone corresponds to a histopathologically defined serrated junctional zone. This study emphasizes three distinct appearances of the junctional zone: adenomyosis of the inner myometrium, junctional zone disease (serrated junctional zone) and linear junctional zone. This classification may be useful in future clinical studies.
© 2018 Nordic Federation of Societies of Obstetrics and Gynecology.

Entities:  

Keywords:  abnormal uterine bleeding; adenomyosis; histopathology; junctional zone; ultrasonography

Mesh:

Year:  2018        PMID: 30317553     DOI: 10.1111/aogs.13484

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  5 in total

1.  Adenomyosis: Mechanisms and Pathogenesis.

Authors:  Junyu Zhai; Silvia Vannuccini; Felice Petraglia; Linda C Giudice
Journal:  Semin Reprod Med       Date:  2020-10-08       Impact factor: 1.303

2.  The effect of transcervical endometrial resection on clinical symptoms related to intrinsic adenomyosis and junctional zone changes.

Authors:  Christina K Rasmussen; Estrid S Hansen; Sham Al-Mashadi Dahl; Erik Ernst; Margit Dueholm
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2019-04-30

3.  Characterization of the Endometrial MSC Marker Ectonucleoside Triphosphate Diphosphohydrolase-2 (NTPDase2/CD39L1) in Low- and High-Grade Endometrial Carcinomas: Loss of Stromal Expression in the Invasive Phenotypes.

Authors:  Aitor Rodríguez-Martínez; Carla Trapero; August Vidal; Josep Maria Piulats; Inmaculada Gómez de Aranda; Jean Sévigny; Maria Eulàlia Fernández-Montolí; Jordi Ponce; Xavier Matias-Guiu; Mireia Martín-Satué
Journal:  J Pers Med       Date:  2021-04-22

Review 4.  Classifying Adenomyosis: Progress and Challenges.

Authors:  Marwan Habiba; Giuseppe Benagiano
Journal:  Int J Environ Res Public Health       Date:  2021-11-25       Impact factor: 3.390

5.  Value of Transabdominal Combined Transvaginal Color Doppler Ultrasonography in the Distinguish between Uterine Adenomyoma and Uterine Fibroids.

Authors:  Hongmei Qi; Changjiang Zhou; Zhenyi Huang; Na Yang; Qun Wu
Journal:  Biomed Res Int       Date:  2022-07-07       Impact factor: 3.246

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.